324 related articles for article (PubMed ID: 30779341)
1. Imiquimod 3.75% for field-directed therapy of actinic keratosis: results of a prospective case-series study in Greece.
Befon A; Tzanetakou V; Panagiotopoulos A; Chasapi V; Antoniou C; Stratigos AJ
Int J Dermatol; 2019 Sep; 58(9):1040-1044. PubMed ID: 30779341
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Imiquimod 3.75% from Lmax in Actinic Keratosis According to Fitzpatrick Skin Type.
Alomar A; Stockfleth E; Dirschka T; Gupta G; Aractingi S; Dakovic R; Peris K
J Drugs Dermatol; 2016 Mar; 15(3):285-9. PubMed ID: 26954313
[TBL] [Abstract][Full Text] [Related]
3. Long-term sustained lesion clearance from Lmax with imiquimod 3.75%, a new field-directed treatment for actinic keratosis.
Gupta G; Stockfleth E; Peris K; Aractingi S; Alomar A; Dakovic R; Dirschka T
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1840-2. PubMed ID: 25174261
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience of imiquimod 3.75% for actinic keratosis: results from a case series.
Tambone S; Fargnoli MC; Capizzi R; Peris K
G Ital Dermatol Venereol; 2018 Jun; 153(3):333-337. PubMed ID: 26439591
[TBL] [Abstract][Full Text] [Related]
5. Lmax and imiquimod 3.75%: the new standard in AK management.
Stockfleth E
J Eur Acad Dermatol Venereol; 2015 Jan; 29 Suppl 1():9-14. PubMed ID: 25470719
[TBL] [Abstract][Full Text] [Related]
6. Reduction in lesions from Lmax: a new concept for assessing efficacy of field-directed therapy for actinic keratosis. Results with imiquimod 3.75%.
Stockfleth E; Gupta G; Peris K; Aractingi S; Dakovic R; Alomar A
Eur J Dermatol; 2014; 24(1):23-7. PubMed ID: 24589500
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of imiquimod 3.75% from Lmax according to the number of actinic keratosis lesions.
Peris K; Stockfleth E; Gupta G; Aractingi S; Dakovic R; Dirschka T; Alomar A
J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2470-3. PubMed ID: 25351284
[TBL] [Abstract][Full Text] [Related]
8. Lmax and imiquimod 3.75% in daily clinical practice.
Gupta G
J Eur Acad Dermatol Venereol; 2015 Jan; 29 Suppl 1():15-8. PubMed ID: 25470720
[TBL] [Abstract][Full Text] [Related]
9. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies.
Swanson N; Smith CC; Kaur M; Goldenberg G
J Drugs Dermatol; 2013 Nov; 12(11):1278-82. PubMed ID: 24196337
[TBL] [Abstract][Full Text] [Related]
10. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles.
Swanson N; Abramovits W; Berman B; Kulp J; Rigel DS; Levy S
J Am Acad Dermatol; 2010 Apr; 62(4):582-90. PubMed ID: 20133013
[TBL] [Abstract][Full Text] [Related]
11. Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial.
Gebauer K; Shumack S; Cowen PS
Br J Dermatol; 2009 Oct; 161(4):897-903. PubMed ID: 19545297
[TBL] [Abstract][Full Text] [Related]
12. Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses.
Quist SR; Gollnick HP
Expert Opin Pharmacother; 2011 Feb; 12(3):451-61. PubMed ID: 21254950
[TBL] [Abstract][Full Text] [Related]
13. Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream.
Shaffelburg M
J Drugs Dermatol; 2009 Jan; 8(1):35-9. PubMed ID: 19180894
[TBL] [Abstract][Full Text] [Related]
14. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Swanson N; Smith CC; Kaur M; Goldenberg G
J Drugs Dermatol; 2014 Feb; 13(2):166-9. PubMed ID: 24509967
[TBL] [Abstract][Full Text] [Related]
15. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles.
Hanke CW; Beer KR; Stockfleth E; Wu J; Rosen T; Levy S
J Am Acad Dermatol; 2010 Apr; 62(4):573-81. PubMed ID: 20133012
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of topical imiquimod 3.75% in the treatment of actinic keratosis of the scalp in immunosuppressed patients: our case series.
Zavattaro E; Veronese F; Landucci G; Tarantino V; Savoia P
J Dermatolog Treat; 2020 May; 31(3):285-289. PubMed ID: 30836026
[No Abstract] [Full Text] [Related]
17. Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis.
Kose O; Koc E; Erbil AH; Caliskan E; Kurumlu Z
J Dermatolog Treat; 2008; 19(3):159-63. PubMed ID: 18569272
[TBL] [Abstract][Full Text] [Related]
18. A 12-Day Course of Imiquimod 5% for the Treatment of Actinic Keratosis: Effectiveness and Local Reactions.
Serra-Guillén C; Nagore E; Llombart B; Sanmartín O; Requena C; Calomarde L; Guillén C
Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):248-253. PubMed ID: 29246367
[TBL] [Abstract][Full Text] [Related]
19. Topical Imiquimod in the Treatment of Conjunctival Actinic Keratosis.
Rowlands MA; Giacometti JN; Servat J; Materin MA; Levin F
Ophthalmic Plast Reconstr Surg; 2017; 33(1):e21-e23. PubMed ID: 25853505
[TBL] [Abstract][Full Text] [Related]
20. Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream.
Torres A; Storey L; Anders M; Miller RL; Bulbulian BJ; Jin J; Raghavan S; Lee J; Slade HB; Birmachu W
J Transl Med; 2007 Jan; 5():7. PubMed ID: 17257431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
